Entelos

Entelos inks deal with Lilly

John Carroll — Thu, 10 Jul 2008 11:55:14 -0400

Shares of the UK's Entelos surged after the company reported a licensing pact with Eli Lilly. The pact covers access to Entelos' database of 630 drug profiles, which is used to test an experimental therapy's safety and toxicity. Report

ALSO NOTED: MonoSol Rx sets IPO; Entelos buys Iconix; and much more...

Thu, 30 Aug 2007 06:59:50 -0400

> MonoSol Rx has set the terms on an IPO of four million shares. The offering is expected to raise up to $70 million if its hits its range of $16 to $18 a share. Report

> Entelos has inked a deal valued at $14.1 million to buy Iconix Biosciences, a predictive toxicology company, in an all-share transaction. "By combining our powerful approaches to better understand efficacy, safety, and new drug uses, the expanded company will be well positioned to take advantage of the synergies and achieve greater commercial success," said Iconix CEO Jim Neal. Release

> Eli Lilly Japan and Takeda Pharmaceutical have axed a deal for the joint development and co-marketing of ruboxistaurin mesylate in Japan after deciding that the diabetes therapy didn't qualify for a Phase III trial. Release

> Sweden's Karo Bio has provided an update on its pipeline programs. Release

> Vermillion--a diagnostic test maker--has closed a private placement for $20 million. Report

> CytoGenix has broken ground on a 20,000 square foot facility to house its offices, laboratory and DNA production plant. Release

> The NIH's new asthma treatment guidelines could be good news for drug companies. FiercePharma

> Four women are suing Sanofi-Aventis for sex discrimination in U.S. federal court. FiercePharma

> Researchers from Geron and the University of Washington have completed new animal studies that offer fresh evidence of the ability of embryonic stem cells to repair the damage done by a heart attack. FierceBioResearcher

And Finally… Dunkin' Donuts says it is eliminating trans fats from its food after developing an alternative cooking oil. Somebody pass me a donut. Report (WSJ sub. req.)

ALSO NOTED: Integra buys IsoTis for $49.3M; MannKind searches for insulin drug partner; and much more...

Tue, 07 Aug 2007 06:59:50 -0400

> Device maker Integra LifeSciences is buying IsoTis for $49.3 million. Release

> MannKind told investors on Friday that it faced an uncertain delay in finding a partner for its inhalable insulin candidate, and investors responded Monday by taking a bite out of the developer's share price. Adding to the uncertainty surrounding the company, MannKind says it is delaying the release of its second-quarter report until Aug. 9 and that CFO Richard Anderson is retiring. The monumental failure of Pfizer's Exubera--an inhalable insulin drug--to find a market niche may be making potential partners particularly skittish. Report

> KineMed has raised $15 million and plans to use the money to advance its lead drug candidate into clinical trials. Release

> Bayer Thai and Schering (Bangkok) have merged. Report

> Isotechnika announced that the FDA has granted fast track designation for its lead drug, ISA247. Release

> Entelos has struck a deal with the FDA to create a computer model for drug-induced liver damage. Release

> Abraxis BioScience has won regulatory approval to sell Oxytocin Injection in a 30 ml vial. Release

> In 2006, Pharma racked up a multibillion-dollar marketing bill. FiercePharma

> PricewaterhouseCoopers has released a study based on interviews with 185 top pharma execs in the Asia-Pacific region. The verdict? Not only are China, India, Singapore and their neighbors poised to become huge pharmaceuticals consumers, but big producers as well. FiercePharma

And Finally… Drinking more than three cups of coffee a day may help women delay memory loss. Report